J Jakob1, A Gerres2, U Ronellenfitsch3, L Pilz2, M Wartenberg4, B Kasper5, H-R Raab6, P Hohenberger7. 1. Spezielle Chirurgische Onkologie und Thoraxchirurgie, Chirurgische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68137, Mannheim, Deutschland. Jens.jakob@umm.de. 2. Medizinische Fakultät Mannheim, Universität Heidelberg, Heidelberg, Deutschland. 3. Klinik für Gefäßchirurgie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland. 4. Das Lebenshaus, Wölfersheim, Deutschland. 5. Interdisziplinäres Tumorzentrum Mannheim, Universitätsmedizin Mannheim, Universität Heidelberg, Heidelberg, Deutschland. 6. Universitätsklinik für Allgemein- und Viszeralchirurgie, Klinikum Oldenburg, Oldenburg, Deutschland. 7. Spezielle Chirurgische Onkologie und Thoraxchirurgie, Chirurgische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68137, Mannheim, Deutschland.
Abstract
OBJECTIVE: Retroperitoneal sarcomas (RPSs) are rare cancers with some variability in clinical and histopathological presentation. In Germany, general treatment strategies of retroperitoneal sarcoma are unknown since centralized registries do not exist. The objective of this survey was to access the medical care of RPS patients in Germany. METHODS: In cooperation with the German Society of General and Visceral surgery, the German Interdisciplinary Sarcoma Study Group and the patient advocacy group Das Lebenshaus we designed an online survey assessing diagnostic and treatment strategies (e. g. performance of tumor biopsies, administration of multimodal therapies and surgical strategy). All departments for general and visceral surgery in Germany were addressed (n = 976). RESULTS: Responses were received from 191 of 976 departments. Only 11 surgical departments treat more than 10 RPS patients per year. A multidisciplinary sarcoma board exists in 19 hospitals. Staging is generally performed by cross-sectional imaging. In 54% of the departments pretreatment tumor biopsy is a standard procedure. Surgery is performed as compartment resection in 85% of the departments. A systematic lymph node dissection is done in 40%. Adjuvant radio- or chemotherapy is performed as a standard treatment in 27% and 22% departments, respectively. CONCLUSION: The survey demonstrates a large heterogeneity in RPS diagnostic and treatment strategies. Dedicated education programs and centralized treatment strategies are warranted to improve the standard of care.
OBJECTIVE:Retroperitoneal sarcomas (RPSs) are rare cancers with some variability in clinical and histopathological presentation. In Germany, general treatment strategies of retroperitoneal sarcoma are unknown since centralized registries do not exist. The objective of this survey was to access the medical care of RPS patients in Germany. METHODS: In cooperation with the German Society of General and Visceral surgery, the German Interdisciplinary Sarcoma Study Group and the patient advocacy group Das Lebenshaus we designed an online survey assessing diagnostic and treatment strategies (e. g. performance of tumor biopsies, administration of multimodal therapies and surgical strategy). All departments for general and visceral surgery in Germany were addressed (n = 976). RESULTS: Responses were received from 191 of 976 departments. Only 11 surgical departments treat more than 10 RPS patients per year. A multidisciplinary sarcoma board exists in 19 hospitals. Staging is generally performed by cross-sectional imaging. In 54% of the departments pretreatment tumor biopsy is a standard procedure. Surgery is performed as compartment resection in 85% of the departments. A systematic lymph node dissection is done in 40%. Adjuvant radio- or chemotherapy is performed as a standard treatment in 27% and 22% departments, respectively. CONCLUSION: The survey demonstrates a large heterogeneity in RPS diagnostic and treatment strategies. Dedicated education programs and centralized treatment strategies are warranted to improve the standard of care.
Entities:
Keywords:
Multimodal therapy; Multivisceral resection; Retroperitoneal sarcoma; Standard of care; Survey
Authors: Syvie Bonvalot; Chandrajit P Raut; Raphael E Pollock; Piotr Rutkowski; Dirk C Strauss; Andrew J Hayes; Frits Van Coevorden; Marco Fiore; Eberhard Stoeckle; Peter Hohenberger; Alessandro Gronchi Journal: Ann Surg Oncol Date: 2012-04-03 Impact factor: 5.344
Authors: Alessandro Gronchi; Dirk C Strauss; Rosalba Miceli; Sylvie Bonvalot; Carol J Swallow; Peter Hohenberger; Frits Van Coevorden; Piotr Rutkowski; Dario Callegaro; Andrew J Hayes; Charles Honoré; Mark Fairweather; Amanda Cannell; Jens Jakob; Rick L Haas; Milena Szacht; Marco Fiore; Paolo G Casali; Raphael E Pollock; Chandrajit P Raut Journal: Ann Surg Date: 2016-05 Impact factor: 12.969
Authors: I Ray-Coquard; P Thiesse; D Ranchère-Vince; F Chauvin; J-Y Bobin; M-P Sunyach; J-P Carret; B Mongodin; P Marec-Bérard; T Philip; J-Y Blay Journal: Ann Oncol Date: 2004-02 Impact factor: 32.976
Authors: Margaret von Mehren; R Lor Randall; Robert S Benjamin; Sarah Boles; Marilyn M Bui; Ernest U Conrad; Kristen N Ganjoo; Suzanne George; Ricardo J Gonzalez; Martin J Heslin; John M Kane; Henry Koon; Joel Mayerson; Martin McCarter; Sean V McGarry; Christian Meyer; Richard J O'Donnell; Alberto S Pappo; I Benjamin Paz; Ivy A Petersen; John D Pfeifer; Richard F Riedel; Scott Schuetze; Karen D Schupak; Herbert S Schwartz; William D Tap; Jeffrey D Wayne; Mary Anne Bergman; Jillian Scavone Journal: J Natl Compr Canc Netw Date: 2016-06 Impact factor: 11.908